$IRON News
Last published 3d ago
- 3d agoIRONGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - DISC MEDICINE INCEarnings Call TranscriptsAll right. Good morning. And thank you for joining Guggenheim's third annual Healthcare Innovations Conference. I am Devjit, one of the therapeutic analysts, and my privilege to host John Quizzle, CEO of Desk Medicines a
- 1w agoIRONDisc Medicine, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoIRONDisc Medicine Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpointsBitopertin NDA resubmission planned by end of 2026, with an FDA decision for
- 1w agoIRONDisc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual MeetingGlobeNewswireTwo oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (PV)Oral
- 1w agoIRONDisc Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 3w agoIRONDisc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common StockGlobeNewswireWATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments
- 3w agoAGIOIRONKROSPTGX+1A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on MondayPR NewswireNEW YORK, Oct. 20, 2026 /CNW/ -- Market Updates News Commentary - Two unrelated announcements on Monday put one of biotech's smaller corners in the spotlight. A company developing a treatment for a rare
- 3w agoIRONDisc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireWATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments
- 3w agoIRONDISC MEDICINE CORPORATE CALL - DISC MEDICINE INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the DISC Medicine Corporate Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session
- 3w agoIRONDisc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)GlobeNewswirePositive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpointsSuccessfully met co-primary endpoints of reduction in protoporphyrin IX (PPIX) and
- 3w agoIRONDisc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)GlobeNewswireWATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 1mo agoIRONMorgan Stanley 24th Annual Global Healthcare Conference - DISC MEDICINE INCEarnings Call TranscriptsGood morning everyone. My name is Sean Larman. I'm the head of SMIDCAP Biotech Equity Research here at Morgan Stanley and welcome to our Global Healthcare Conference. Before we begin, just to make you aware of some impor
- 1mo agoIRONMorgan Stanley 24th Annual Global Healthcare Conference - DISC MEDICINE INCEarnings Call TranscriptsGood morning everyone. My name is Sean Larman. I'm the head of SMIDCAP Biotech Equity Research here at Morgan Stanley and welcome to our Global Healthcare Conference. Before we begin, just to make you aware of some impor
- 2mo agoIRONWells Fargo 21st Annual Healthcare Conference - DISC MEDICINE INCEarnings Call TranscriptsAll right. Good morning, everybody. I think we'll get started here with the first fireside this morning. My name is Derek Archilla. I'm one of the senior biotech analysts here at Wells Fargo. Very excited to be joined by
- 2mo agoIRONWells Fargo 21st Annual Healthcare Conference - DISC MEDICINE INCEarnings Call TranscriptsAll right. Good morning, everybody. I think we'll get started here with the first fireside this morning. My name is Derek Archilla. I'm one of the senior biotech analysts here at Wells Fargo. Very excited to be joined by
- 2mo agoIRONDisc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual MeetingGlobeNewswireInitial results from RESTORE-PV show DISC-3405 increased hepcidin and lowered serum iron, translating to controlled hematocrit, reduced phlebotomy, and improved symptoms in PV patientsDISC-3405 is the first monoclonal
- 2mo agoIRONDisc Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 2mo agoIRONDisc Medicine Announces Multiple Presentations Across Portfolio at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingGlobeNewswireWATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 3mo agoIRONDisc Medicine Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireCompleted Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded Access Program
- 5mo agoIRONDisc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual MeetingGlobeNewswireData from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or
- 5mo agoIRONDisc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic ProtoporphyriaGlobeNewswireAligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission by end of 2026
- 5mo agoIRONJefferies Global Healthcare Conference in New York - DISC MEDICINE INCEarnings Call TranscriptsWelcome everyone to Jefferies' 2026 Global Healthcare Conference. My name is Roger Song, senior at Covers Mid-Cap Biotech. It is my pleasure to have the fireside chat with our next company, Disco Medicine, and then we ha
- 5mo agoIRONDisc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireDemonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN,
- 5mo agoIRONDisc Medicine Launches Expanded Access Program for Bitopertin for EPP PatientsGlobeNewswireThe expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decisionBitopertin, an oral glycine transporter 1 (GlyT1)
- 6mo agoIRONDisc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 CongressGlobeNewswireOral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemiaAdditional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT
- 6mo agoIRONDisc Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 6mo agoIRONDisc Medicine Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireCompleted enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026Updated data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis
- 6mo agoIRONDisc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireWATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 7mo agoIRONDisc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic ProtoporphyriaGlobeNewswireLast participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and physician demandResults of
- 8mo agoMLYSPROKIRONREGN+5Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsightPR NewswireRecently published Chronic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, chronic...
- 8mo agoIRONDisc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswirePursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026Initial data from
- 8mo agoIRONDisc Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 8mo agoIRONDISC MEDICINE CORPORATE CALLDISC MEDICINE INCEarnings Call TranscriptsGood day, and thank you for standing by. Welcome to the DISC Medicine Corporate Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer sessio
- 9mo agoIRONDisc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPPGlobeNewswireFDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the PPIX biomarker
- 10mo agoIRONDisc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources OfficerGlobeNewswireWATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 10mo agoIRONDisc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026GlobeNewswireBitopertin was awarded the Commissioner's National Priority Review Voucher (CNPV) and NDA is currently under FDA reviewUpdated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia
- 11mo agoIRONDisc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswireDemonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN, Mass.,
- 1y agoIRONDisc Medicine Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireSubmitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher (CNPV), which is
- 1y agoIRONDisc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswireWATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 1y agoIRONDisc Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 1y agoIRONDisc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireWATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments
- 1y agoIRONDisc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireWATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments
- 1y agoIRONDisc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated MilestonesGlobeNewswireSubmitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and subsequently was awarded the FDA Commissioner's National Priority Voucher
- 1y agoIRONDisc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney WeekGlobeNewswireWATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 1y agoIRONDisc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)GlobeNewswireDisc is seeking accelerated approval of bitopertin for patients aged 12 years and older with EPPThe CNPV program is designed to reduce the drug application review process to 1-2 months WATERTOWN, Mass., Oct. 16, 2025
- 1y agoIRONDisc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)GlobeNewswireDisc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30, 2025 (GLOBE
- 1y agoIRONDisc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoIRONDisc Medicine to Participate in Upcoming Investor ConferencesGlobeNewswireWATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for
- 1y agoIRONSTTKShattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of DirectorsGlobeNewswire— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma
- 1y agoIRONDisc Medicine Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireCompany on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful pre-NDA meetingExpect initial data from Phase 2 study of